Cargando…

Homoharringtonine targets Smad3 and TGF-β pathway to inhibit the proliferation of acute myeloid leukemia cells

Homoharringtonine (HHT) has long and widely been used in China for the treatment of acute myeloid leukemia (AML), the clinical therapeutic effect is significant but the working mechanism is poorly understood. The purpose of this study is to screen the possible target for HHT with virtual screening a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Jian, Mu, Qitian, Li, Xia, Yin, Xiufeng, Yu, Mengxia, Jin, Jing, Li, Chenying, Zhou, Yile, Zhou, Jiani, Suo, Shanshan, Lu, Demin, Jin, Jie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5522237/ https://www.ncbi.nlm.nih.gov/pubmed/28454099 http://dx.doi.org/10.18632/oncotarget.16956

Ejemplares similares

The combination effect of homoharringtonine and ibrutinib on FLT3-ITD mutant acute myeloid leukemia
por: Li, Xia, et al.
Publicado: (2017)

Correction: The combination effect of homoharringtonine and ibrutinib on FLT3-ITD mutant acute myeloid leukemia
por: Li, Xia, et al.
Publicado: (2019)

Homoharringtonine exhibits potent anti-tumor effect and modulates DNA epigenome in acute myeloid leukemia by targeting SP1/TET1/5hmC
por: Li, Chenying, et al.
Publicado: (2020)

Synergistic Lethality Effects of Apatinib and Homoharringtonine in Acute Myeloid Leukemia
por: Shi, Yuanfei, et al.
Publicado: (2022)

Curcumin in combination with homoharringtonine suppresses lymphoma cell growth by inhibiting the TGF-β/Smad3 signaling pathway
por: Zhang, Yu, et al.
Publicado: (2021)

Prognostic impact of MYH9 expression on patients with acute myeloid leukemia
por: Yu, Mengxia, et al.
Publicado: (2016)

Synergistic efficacy of homoharringtonine and venetoclax on acute myeloid leukemia cells and the underlying mechanisms
por: Yuan, Fangfang, et al.
Publicado: (2022)

Homoharringtonine is synergistically lethal with BCL-2 inhibitor APG-2575 in acute myeloid leukemia
por: Wei, Wenwen, et al.
Publicado: (2022)

Correction for: Curcumin in combination with homoharringtonine suppresses lymphoma cell growth by inhibiting the TGF-β/Smad3 signaling pathway
por: Zhang, Yu, et al.
Publicado: (2022)

Homoharringtonine and omacetaxine for myeloid hematological malignancies
por: Lü, Shuqing, et al.
Publicado: (2014)

The Basic Research of the Combinatorial Therapy of ABT-199 and Homoharringtonine on Acute Myeloid Leukemia
por: Shi, Yuanfei, et al.
Publicado: (2021)

P507: SALVAGE THERAPY WITH VENETOCLAX IN COMBINATION WITH AZACITIDINE, HOMOHARRINGTONINE AND CYTARABINE IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA
por: Yuan, Linyu, et al.
Publicado: (2023)

ACC010, a novel BRD4 inhibitor, synergized with homoharringtonine in acute myeloid leukemia with FLT3 ‐ITD
por: Qian, Yu, et al.
Publicado: (2023)

Synergistic cytotoxicity of homoharringtonine and etoposide in acute myeloid leukemia cells involves disrupted antioxidant defense
por: Zhang, Jingjing, et al.
Publicado: (2019)

Synergistic killing effects of homoharringtonine and arsenic trioxide on acute myeloid leukemia stem cells and the underlying mechanisms
por: Tan, Ming, et al.
Publicado: (2019)

MiR-370 sensitizes chronic myeloid leukemia K562 cells to homoharringtonine by targeting Forkhead box M1
por: Zhou, MinRan, et al.
Publicado: (2013)

Homoharringtonine suppresses imatinib resistance via the Bcl-6/p53 pathway in chronic myeloid leukemia cell lines
por: Wang, Qian, et al.
Publicado: (2017)

Correction to: Synergistic killing effects of homoharringtonine and arsenic trioxide on acute myeloid leukemia stem cells and the underlying mechanisms
por: Tan, Ming, et al.
Publicado: (2019)

HAG (Homoharringtonine, Cytarabine, G-CSF) Regimen for the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Meta-Analysis with 2,314 Participants
por: Xie, Mixue, et al.
Publicado: (2016)

Efficacy and safety of decitabine combined with HAAG (homoharringtonine, aclarubicin, low-dose cytarabine and G-CSF) for newly diagnosed acute myeloid leukemia
por: Zhu, Jun-Feng, et al.
Publicado: (2022)

Homoharringtonine combined with cladribine and aclarubicin (HCA) in acute myeloid leukemia: A new regimen of conventional drugs and its mechanism
por: Wang, Fenglin, et al.
Publicado: (2022)

Homoharringtonine enhances the effect of imatinib on chronic myelogenous leukemia cells by downregulating ZFX
por: Wu, Jingjing, et al.
Publicado: (2019)

Prognostic and therapeutic implications of iron-related cell death pathways in acute myeloid leukemia
por: Li, Tongyu, et al.
Publicado: (2023)

High PARP-1 expression predicts poor survival in acute myeloid leukemia and PARP-1 inhibitor and SAHA-bendamustine hybrid inhibitor combination treatment synergistically enhances anti-tumor effects
por: Li, Xia, et al.
Publicado: (2018)

A homoharringtonine-based induction regimen for the treatment of elderly patients with acute myeloid leukemia: a single center experience from China
por: Wang, Jianmin, et al.
Publicado: (2009)

Homoharringtonine-Based Induction Therapy Reduces the Recurrence Rate of Pediatric Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation
por: Wang, Bin, et al.
Publicado: (2023)

Homoharringtonine Combined with the Heat Shock Protein 90 Inhibitor IPI504 in the Treatment of FLT3-ITD Acute Myeloid Leukemia
por: Wu, Zhaoxing, et al.
Publicado: (2019)

Hsa_circ_0012152 and Hsa_circ_0001857 Accurately Discriminate Acute Lymphoblastic Leukemia From Acute Myeloid Leukemia
por: Guo, Shanshan, et al.
Publicado: (2020)

Homoharringtonine Synergized with Gilteritinib Results in the Downregulation of Myeloid Cell Leukemia-1 by Upregulating UBE2L6 in FLT3-ITD-Mutant Acute Myeloid (Leukemia) Cell Lines
por: Cai, Jiayi, et al.
Publicado: (2021)

Acute myeloid leukemia in an 86-year-old man with AML1/ETO treated with Homoharringtonine and Arsenic Trioxide: A case report
por: He, Zhipeng, et al.
Publicado: (2019)

β-Sitosterol Inhibits The Proliferation of Endometrial Cells via Regulating Smad7-Mediated TGF-β/Smads Signaling Pathway
por: Wen, Yi, et al.
Publicado: (2023)

The Metabolic Signature of AML Cells Treated With Homoharringtonine
por: Zhang, Yulong, et al.
Publicado: (2022)

10058-F4, a c-Myc inhibitor, markedly increases valproic acid-induced cell death in Jurkat and CCRF-CEM T-lymphoblastic leukemia cells
por: MU, QITIAN, et al.
Publicado: (2014)

The Natural Compound Homoharringtonine Presents Broad Antiviral Activity In Vitro and In Vivo
por: Dong, Hui-Jun, et al.
Publicado: (2018)

Long non-coding RNA MIR17HG sponges microRNA-21 to upregulate PTEN and regulate homoharringtonine-based chemoresistance of acute myeloid leukemia cells
por: Yan, Jinhua, et al.
Publicado: (2022)

Effectiveness of chemotherapy using bortezomib combined with homoharringtonine and cytarabine in refractory or relapsed acute myeloid leukemia: a phase II, multicenter, prospective clinical trial
por: Zhang, Chengtao, et al.
Publicado: (2023)

miR-550-1 functions as a tumor suppressor in acute myeloid leukemia via the hippo signaling pathway
por: Hu, Chao, et al.
Publicado: (2020)

P584: VENETOCLAX PLUS HOMOHARRINGTONINE-BASED CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR ADULTS WITH ACUTE MYELOID LEUKAEMIA: A MULTICENTRE, SINGLE-ARM, PHASE 2 TRIAL
por: Wang, Huafeng, et al.
Publicado: (2023)

NANOG regulates the proliferation of PCSCs via the TGF-β1/SMAD pathway
por: Liu, Changming, et al.
Publicado: (2020)

Characterization of the Newly Established Homoharringtonine- (HHT-) Resistant Cell Lines and Mechanisms of Resistance
por: Li, Fenglin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9j6bn3b65s75f34qepecpi917v